Blood, Plasma, and Plasma Proteins: A Unique Contribution to Modern Healthcare
"Labile blood products and plasma-derived products are very sensitive from a social viewpoint. Along with the challenges faced by all medicinal products there is an added challenge due to the lack of raw material and the social problems with regards to their acquisition. Obtaining them depends on blood and plasma donations, which are insufficient. Europeans as a whole fail to even cover 40 % of their needs in plasma for fractionation. The aspiration that all donations shall be voluntary, free and unpaid, is an altruistic objective, which reality, unfortunately, contradicts every day. Governments and all social agencies should promote to the maximum its actions in order to achieve the greatest number of donation each day. Even from a humanitarian or ethical viewpoint nobody can deny a possible donor accepting incentives. This incentive discussion, plus the concept of selfsufficiency of countries and more are discussed in this volume."
What people are saying - Write a review
We haven't found any reviews in the usual places.
J van Rhenen
J P Betts
Delivering therapy to Alpha1 patients
von Hoegen and M Gustafson
Directive 89381EEC of June 1989
Directive 200298EC of the European Parliament and of the Council of 27
Commission Directive 200433EC of 22 March 2004
Author Index Volume 7 20052006
albumin antibodies apheresis Article Balanced Production bleeding blood and blood blood and plasma blood components blood donation blood establishments blood products Blood Safety blood transfusion Centres for Study clinical coagulation factors concentrates cost deficiency derived from human derived medicinal products diagnosis Directive disease disorders dysfibrinogenemia effective ensure Europe European Parliament European Union Factor IX Factor VIII Factor XIII deficiency fibrinogen FVIII guidelines haemophilia healthcare hepatitis hospital human blood human plasma immune immunoglobulin important inactivation industry infections intravenous IOS Press IVIG manufacturing medicinal products derived Network of Centres organisation patients Pharmaceutical Law plasma collection plasma derived medicinal plasma donors plasma fractionation plasma products plasma protein therapies plasmapheresis platelets primary immunodeficiency procedures quality and safety recombinant red cells regulations regulatory requirements risk self-sufficiency specific storage Study of Pharmaceutical testing therapeutic transmission vCJD viral virus viruses whole blood donation